Sente, Inc., recently announced the appointment of Michael York as president, chief executive officer and a member of the board of directors. York joins Sente after more than 20 years in management and leadership positions at Amylin Pharmaceuticals; Santarus, Inc.; Amgen; and AstraZeneca.
New Advances in Treating Hyperpigmentation
This past decade has seen an enormous surge in popularity of skin brightening products formulated specifically to treat hyperpigmentation and…

0 Comments